7,986 results match your criteria: "The Lancet. Infectious diseases[Journal]"
Weighing up monoclonals and vaccination against COVID-19.
Lancet Infect Dis
January 2025
RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK. Electronic address:
Mpox-is there a more dangerous new clade?
Lancet Infect Dis
November 2024
ICH Study Center, Hamburg 20095, Germany; Department of Medicine II, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. Electronic address:
Oropouche virus genomic surveillance in Brazil.
Lancet Infect Dis
November 2024
Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil; Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address:
Oropouche fever: reports of vertical transmission and deaths in Brazil.
Lancet Infect Dis
November 2024
Central Laboratory of Public Health (LACEN/SE), Government of Sergipe State, Aracaju, SE, 49020-590, Brazil.
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance.
Lancet Infect Dis
October 2024
STI Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium; Division of Infectious Diseases and HIV Medicine, University of Cape Town, Cape Town, South Africa. Electronic address:
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south.
Lancet Infect Dis
October 2024
Pathogen Hunter's Research Collaborative Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata 990-2292, Japan. Electronic address:
Re-evaluating polio vaccination strategies in Nepal: transitioning from OPV to fIPV for sustained immunity.
Lancet Infect Dis
October 2024
Government of Nepal, Ministry of Health and Population, Kathmandu, Nepal.
Strongyloides stercoralis hyperinfection syndrome.
Lancet Infect Dis
September 2024
Department of Infectious Diseases, Institute of Post-Graduate Medical Education and Research, Kolkata, India.
Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.
Lancet Infect Dis
September 2024
Harvard Medical School Department of Global Health and Social Medicine, Boston, MA 02115, USA. Electronic address:
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus.
Lancet Infect Dis
October 2024
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; Institute for Global Health and Development, Peking University, Beijing 100871, China. Electronic address:
Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study.
Lancet Infect Dis
December 2024
Department of Virology, Institut National de la Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Department of Medical Biology, Cliniques Universitaires de Kinshasa, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Background: The recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine is the only WHO prequalified vaccine recommended for use to respond to outbreaks of Ebola virus (species Zaire ebolavirus) by WHO's Strategic Advisory Group of Experts on Immunization. Despite the vaccine's widespread use during several outbreaks, no real-world effectiveness estimates are currently available in the literature.
Methods: We conducted a retrospective test-negative analysis to estimate effectiveness of rVSV-ZEBOV vaccination against Ebola virus disease during the 2018-20 epidemic in the Democratic Republic of the Congo, using data on suspected Ebola virus disease cases collected from Ebola treatment centres.
Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine.
Lancet Infect Dis
December 2024
MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK; London School of Hygiene & Tropical Medicine, London, UK.
Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.
Lancet Infect Dis
October 2024
Division of Systems Virology, Department of Microbiology and Immunology, The University of Tokyo, Tokyo 113-0033, Japan; International Research Center for Infectious Diseases, The University of Tokyo, Tokyo 113-0033, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 113-0033, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, UK. Electronic address:
Resistant malaria parasites gaining momentum in Africa.
Lancet Infect Dis
November 2024
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7925, South Africa; WorldWide Antimalarial Resistance Network, Pharmacology Scientific Module and South-East African Regional Centre, Department of Medicine, University of Cape Town, Cape Town 7925, South Africa. Electronic address: